Table 4.
Testicular | Current Role | Mechanism | Outcomes |
---|---|---|---|
Brentuximab vedotin | Highly pre-treated patients with germ-cell tumors | Antibody-drug conjugate | Early signs of clinical activity and immunomodulatory effects |
Immune checkpoint inhibitors | Seminoma and non-seminomatous germ-cell tumors | Checkpoint inhibitors | An option, 73% expression PD-L1 |